Post-Authorisation Safety Study of Lesinurad

Trial Identifier: D5310R00016
Sponsor: AstraZeneca
NCTID:: NCT04072471
Start Date: January 2021
Primary Completion Date: June 2023
Study Completion Date: June 2023
Condition: Immune, Inflammatory & Infections - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Italy, Tuscany Firenze, Tuscany, Italy, 50142
Spain, Barcelona Barcelona, Spain, 08007
USA, Delaware Wilmington, Delaware, USA, 19801 - 1437
USA, Kansas Lawrence, Kansas, USA, 66044